Resumo

GUTIERREZ-PASTOR, Iván. Mucocutaneous toxicity: a challenge in oncological treatment. Hosp. domic. [online]. 2023, vol.7, n.3, pp.149-155.  Epub 08-Jan-2024. ISSN 2530-5115.  https://dx.doi.org/10.22585/hospdomic.v7i3.197.

The combined treatment with tyrosine kinase inhibitors and immunotherapy in advanced lung cancer with EGFR mutation is an emerging approach in clinical research. Some preliminary studies have shown promising results, with improvements in tumor response and overall survival compared to monotherapy. However, this combination may increase the risk of adverse events, necessitating close monitoring and specialized medical attention. We present the case of a 57-year-old male with lung adenocarcinoma who manifested grade 3 generalized exanthema with papulopustular lesions, paronychia and trichomegaly secondary to treatment with lazertinib-amivantamab. Additionally, the patient developed chronic proctalgia with poorly controlled pain due to the presence of anal ulcers and anal sphincter hypertonia.

Palavras-chave : Drug-Related Side Effects and Adverse Reactions; Exanthema; Fissure in Ano; Carcinoma, Non-Small-Cell Lung.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )